What is CJC-1295 without DAC 5mg + IPA 5mg?
CJC-1295 without DAC (5 mg) + Ipamorelin (5 mg) is a dual-peptide research formulation referenced in laboratory studies examining growth hormone–related signaling, metabolic regulation, and neuroendocrine communication. The formulation contains a total peptide strength of 10 mg, composed of two synthetically produced peptides with complementary signaling profiles.
CJC-1295 without DAC, also known as Modified GRF (1-29), is a 29-amino-acid fragment derived from growth hormone–releasing hormone (GHRH). The absence of the drug affinity complex (DAC) results in a short-acting signaling profile, making it suitable for experimental models focused on acute endocrine signaling dynamics.
Ipamorelin is a synthetic pentapeptide investigated in research models for its selective interaction with ghrelin-associated growth hormone secretagogue receptors (GHSR-1a). In contrast to broader secretagogues, ipamorelin is studied for its receptor selectivity and limited interaction with non-target endocrine pathways under controlled laboratory conditions.
Together, this combination—commonly referred to in research environments as a CJC-1295 / Ipamorelin combo—allows investigators to explore how distinct peptide pathways may function concurrently within a single experimental framework. All observations are investigational and limited to in vitro and preclinical research models, with no clinical or therapeutic implications.
What are the key features of CJC-1295 without DAC 5mg + IPA 5mg?
This dual-peptide formulation is supplied as lyophilized powders designed for precise laboratory handling and reproducibility. Key features include:
- Synthetic peptide manufacturing for batch consistency
- Lyophilized, laboratory-ready presentation
- Investigated in endocrine and metabolic research models
- Verified using HPLC and mass spectrometry (MS)
- Compatible with standard peptide handling protocols
- Intended strictly for laboratory research use only
3. How is CJC-1295 without DAC 5mg + IPA 5mg synthesized?
This formulation contains two synthetic peptides supplied within a single vial at the following verified quantities, for a total vial content of 10 mg:
- CJC-1295 (No DAC): 5 mg
- CAS: 863288-34-0
- Molecular Weight: 33,367.95 g/mol
- Chemical Formula: C₁₅₂H₂₅₂N₄₄O₄₂
- Synonyms: MOD-GRF(1-29), CJC-1295 without DAC, modGRF, modified GRF
- Peptide Sequence:
Tyr–D-Ala–Asp–Ala–Ile–Phe–Thr–Gln–Ser–Tyr–Arg–Lys–Val–Leu–Ala–Gln–Leu–Ser–Ala–Arg–Lys–Leu–Leu–Gln–Asp–Ile–Leu–Ser–Arg
- Ipamorelin: 5 mg
- CAS: 170851-70-4
- Molecular Weight: 711.85 g/mol
- Peptide Sequence:
Aib–His–D-2-Nal–D-Phe–Lys–NH₂
- Synonyms: Ipamorelin acetate, IPAM, NNC-26-0161
CJC-1295 without DAC is a 29-amino-acid GHRH fragment designed to support short-term receptor signaling studies, while ipamorelin is a pentapeptide secretagogue studied for its selective ghrelin-receptor–mediated activity. The combination enables researchers to examine parallel but mechanistically distinct endocrine signaling pathways in controlled experimental systems.
Both peptides are supplied as high-purity lyophilized powders, with identity and purity typically confirmed using HPLC and mass spectrometry. This standardized presentation supports accuracy, reproducibility, and consistency across laboratory workflows.
What is CJC-1295 without DAC 5mg + IPA 5mg being studied for? What are its possible benefits?
CJC-1295 without DAC and ipamorelin have been studied in research models for their potential impact on metabolic regulation, cellular growth mechanisms, and neuroendocrine pathways. CJC-1295 fragments without DAC have been examined for effects on short-term signaling cascades. At the same time, ipamorelin has been investigated for its selective interaction with pathways involved in cell repair and energy utilization. These are ongoing areas of laboratory exploration and remain investigational.
Research has explored this combination for its potential effects on several biological systems in preclinical models:
- Growth hormone secretion patterns and pituitary function
- Protein synthesis and metabolic processes
- Cellular recovery and regeneration mechanisms
- Neuroendocrine signaling pathways
- Nutrient utilization in model organisms
Because these findings are preliminary and limited to laboratory environments, all potential biological effects remain theoretical and unproven. Research in this area continues to examine how the CJC-1295 ipamorelin combo may influence measurable markers in controlled experiments.
How does CJC-1295 without DAC 5mg + IPA 5mg work in research studies?
In research studies, CJC-1295 without DAC and ipamorelin are investigated for their potential effects on growth hormone through two distinct mechanisms.
CJC-1295 without DAC has been studied for its interaction with growth hormone-releasing hormone (GHRH) pathways in laboratory models. It is researched for how it may influence pituitary gland function related to growth hormone secretion. Meanwhile, ipamorelin is investigated for its potential effects through ghrelin-related pathways. These two peptides have shown potential for complementary interaction because they target different biological mechanisms.
When combined, researchers examine how these two peptides may produce synergistic effects in preclinical models and cellular experiments. All observations remain limited to controlled laboratory environments and do not represent therapeutic effects or clinical applications.
What dosing information exists for CJC-1295 without DAC 5mg + IPA 5mg?
Because this combination is restricted to scientific use, no standardized dosing guidelines exist. Preclinical research has employed various dosing approaches depending on the study type:
- In vitro cellular assays: 10–100 nM (nanomolar concentrations)
- In vivo murine models: 5–20 µg/kg (micrograms per kilogram body weight)
Note: These represent different measurement systems appropriate to their respective study types. Nanomolar (nM) concentrations apply to cell-based experiments, while micrograms per kilogram (µg/kg) applies to whole-animal dosing. These values vary significantly depending on the research design, experimental endpoints, and laboratory-specific methodology. No human dosing guidelines exist for this research-grade combination.
How should CJC-1295 without DAC 5mg + IPA 5mg be stored and handled?
Lyophilized materials should generally be stored at –20 °C in a sealed, moisture-free environment. Protection from light and repeated freeze–thaw cycles is recommended to maintain structural integrity. After reconstitution with a suitable laboratory-grade solvent, solutions may be stored short-term at 2–8 °C for limited periods based on the laboratory’s own stability evaluations.
Long-term storage recommendations are based on standard peptide-handling guidelines, which recommend minimizing exposure to air and temperature fluctuations. Researchers planning to buy CJC 1295 ipamorelin combo for laboratory use typically follow similar storage principles to ensure consistency and reliability during experimental work.
Where can I read more research about CJC-1295 without DAC 5mg + IPA 5mg?
Additional peer-reviewed information can be found in studies exploring peptide analogues, metabolic signaling, and growth-related pathways. Relevant sources include:
- https://pubmed.ncbi.nlm.nih.gov/16822960/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC5383112/
- https://academic.oup.com/jcem/article-abstract/91/3/799/2843281
- https://link.springer.com/article/10.1023/a:1018955126402
Compliance Statement
This product is intended for laboratory research use only and is not approved for human or veterinary use.